Skip to main content

Table 1 Changes in blood serum chemistry after the treatment with IL13-PE38QQR

From: Improved Anti-tumor Activity and Safety of Interleukin-13 Receptor Targeted Cytotoxin by Systemic Continuous Administration in Head and Neck Cancer Xenograft Model

Profile

Reference Range (Units)

Intravenous Administration

Continuous Infusion

Control*

150 µ g/kg

Control

200 µ g/kg

300 µ g/kg

Sodium

150–162 (mEq/l)

150

141

151

152

144

Potassium

3.8–6.8 (mEq/l)

6.0

20.1

5.7

5.8

16.3

CPK+

0–800 (U/l)

179

14414

60

471

6665

LDH

260–680 (U/l)

1083

5032

663

1353

2490

AST (GOT)

72–288 (U/l)

208

1482

70

125

565

ALT (GPT)

24–140 (U/l)

76

723

28

88

91

Albumin

2.6–4.6 (g/dl)

2.8

1.9

2.5

2.7

3.4

  1. * Data represent the mean of blood samples from two animals from each group.
  2. † CPK, creatinine phosphokinase.